HK Stock MarketDetailed Quotes

02607 SH PHARMA

Watchlist
  • 11.320
  • +0.100+0.89%
Market Closed Apr 26 16:08 CST
41.92BMarket Cap10.02P/E (TTM)

SH PHARMA Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

All
YOY yoy
Hide blank lines yoy
(Q3)Mar 31, 2024
(FY)Dec 31, 2023
(Q9)Sep 30, 2023
(Q6)Jun 30, 2023
(Q3)Mar 31, 2023
(FY)Dec 31, 2022
(Q9)Sep 30, 2022
(Q6)Jun 30, 2022
(Q3)Mar 31, 2022
(FY)Dec 31, 2021
Turnover
5.93%70.15B
12.21%260.3B
13.11%197.51B
18.70%132.59B
16.39%66.23B
7.49%231.98B
8.47%174.61B
6.15%111.71B
10.27%56.9B
12.46%215.82B
Operating income
5.93%70.15B
12.21%260.3B
13.11%197.51B
18.70%132.59B
16.39%66.23B
7.49%231.98B
8.47%174.61B
6.15%111.71B
10.27%56.9B
12.46%215.82B
Operating expenses
-7.87%-62.12B
-13.63%-228.97B
-14.22%-173.55B
-19.50%-115.53B
-16.19%-57.59B
-7.59%-201.49B
-9.10%-151.93B
-5.98%-96.68B
-11.02%-49.57B
-13.38%-187.28B
Gross profit
-7.03%8.03B
2.76%31.33B
5.67%23.96B
13.51%17.06B
17.80%8.63B
6.81%30.49B
4.45%22.68B
7.26%15.03B
5.41%7.33B
6.79%28.54B
Selling expenses
15.86%-3.29B
2.64%-13.9B
-1.29%-10.47B
-13.81%-7.73B
-18.05%-3.91B
-7.22%-14.28B
-1.18%-10.34B
-7.42%-6.79B
-4.23%-3.31B
-9.53%-13.32B
Administrative expenses
-0.90%-1.39B
-14.43%-5.71B
-11.62%-4.19B
-19.00%-2.76B
-15.70%-1.38B
2.95%-4.99B
-5.09%-3.76B
0.03%-2.32B
2.57%-1.19B
-8.70%-5.14B
Research and development expenses
7.26%-501.45M
-4.35%-2.2B
-5.70%-1.47B
-26.76%-1.03B
-20.82%-540.69M
-6.29%-2.11B
-1.63%-1.39B
7.99%-809.67M
-7.95%-447.5M
-19.96%-1.99B
Profit from asset sales
405.21%110.04M
-93.57%92.48M
-92.67%104.58M
-94.83%73.75M
188.72%21.78M
2,368.58%1.44B
22,234.19%1.43B
23,988.34%1.43B
7,912.76%7.54M
11.77%58.29M
Revaluation surplus
-41.55%52.25M
85.03%404.73M
225.04%239.02M
675.23%196.84M
240.65%89.4M
206.18%218.74M
141.65%73.54M
171.34%25.39M
47.56%-63.56M
-276.38%-206M
-Changes in the fair value of other assets
-41.55%52.25M
85.03%404.73M
225.04%239.02M
675.23%196.84M
240.65%89.4M
206.18%218.74M
141.65%73.54M
171.34%25.39M
47.56%-63.56M
-276.38%-206M
Impairment and provision
-42.34%-241.8M
-30.64%-841.24M
-15.91%-262.6M
-51.60%-270.22M
-362.28%-169.87M
-360.73%-643.93M
13.13%-226.55M
3.90%-178.24M
60.88%-36.75M
83.73%-139.76M
-Other impairment is provision
-42.34%-241.8M
-30.64%-841.24M
-15.91%-262.6M
-51.60%-270.22M
-362.28%-169.87M
-360.73%-643.93M
13.13%-226.55M
3.90%-178.24M
60.88%-36.75M
83.73%-139.76M
Special items of operating profit
-34.56%233.27M
-21.78%725.04M
-49.72%346.45M
-61.50%171.36M
41.47%356.49M
-59.88%926.88M
-67.03%689.04M
-76.12%445.11M
-83.73%251.99M
51.48%2.31B
Operating profit
-4.11%2.79B
-11.38%9.15B
-10.54%7.71B
-17.32%5.33B
23.59%2.91B
9.28%10.33B
11.48%8.62B
11.00%6.45B
-28.85%2.35B
12.19%9.45B
Financing cost
10.46%-374.43M
-13.14%-1.49B
-15.71%-1.15B
-19.16%-773.22M
-16.64%-418.18M
-5.45%-1.31B
-7.26%-997.59M
-12.10%-648.91M
-13.43%-358.53M
-0.47%-1.25B
Special items of earning before tax
54.93%2.02M
-197.11%-612.94M
30.84%-36.96M
41.10%-24.29M
115.24%1.3M
-234.51%-206.3M
-1,031.28%-53.44M
-228.25%-41.24M
-261.75%-8.55M
-592.50%-61.67M
Earning before tax
-3.02%2.42B
-19.91%7.05B
-13.86%6.52B
-21.26%4.53B
25.44%2.49B
8.16%8.81B
11.35%7.57B
10.36%5.76B
-33.72%1.99B
13.50%8.14B
Tax
-2.28%-551.13M
-3.93%-1.89B
1.16%-1.57B
6.45%-1.12B
-18.63%-538.85M
2.83%-1.82B
-10.54%-1.58B
-13.39%-1.19B
26.63%-454.25M
-19.04%-1.87B
After-tax profit from continuing operations
-4.48%1.87B
-26.11%5.17B
-17.22%4.95B
-25.14%3.42B
27.46%1.95B
11.43%6.99B
11.56%5.98B
9.59%4.56B
-35.56%1.53B
11.94%6.27B
Earning after tax
-4.48%1.87B
-26.11%5.17B
-17.22%4.95B
-25.14%3.42B
27.46%1.95B
11.43%6.99B
11.56%5.98B
9.59%4.56B
-35.56%1.53B
11.94%6.27B
Minority profit
-25.75%323.29M
1.72%1.4B
-1.14%1.16B
-7.07%807.18M
54.77%435.4M
16.41%1.37B
33.04%1.17B
45.49%868.61M
9.10%281.31M
6.50%1.18B
Profit attributable to shareholders
1.62%1.54B
-32.92%3.77B
-21.13%3.8B
-29.38%2.61B
21.31%1.52B
10.28%5.62B
7.35%4.81B
3.58%3.7B
-40.99%1.25B
13.28%5.09B
Basic earnings per share
2.44%0.42
-36.65%1.02
-28.97%1.03
-37.17%0.71
-6.82%0.41
-10.06%1.61
-8.23%1.45
-10.32%1.13
-41.33%0.44
13.29%1.79
Diluted earnings per share
2.44%0.42
-36.65%1.02
-28.97%1.03
-37.17%0.71
-6.82%0.41
-10.06%1.61
-8.23%1.45
-10.32%1.13
-41.33%0.44
13.29%1.79
Currency Unit
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
Accounting Standards
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
Audit Opinions
--
Unqualified Opinion
--
--
--
Unqualified Opinion
--
--
--
Unqualified Opinion
Auditor
--
PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership)
--
--
--
PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership)
--
--
--
PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership)
(Q3)Mar 31, 2024(FY)Dec 31, 2023(Q9)Sep 30, 2023(Q6)Jun 30, 2023(Q3)Mar 31, 2023(FY)Dec 31, 2022(Q9)Sep 30, 2022(Q6)Jun 30, 2022(Q3)Mar 31, 2022(FY)Dec 31, 2021
Turnover 5.93%70.15B12.21%260.3B13.11%197.51B18.70%132.59B16.39%66.23B7.49%231.98B8.47%174.61B6.15%111.71B10.27%56.9B12.46%215.82B
Operating income 5.93%70.15B12.21%260.3B13.11%197.51B18.70%132.59B16.39%66.23B7.49%231.98B8.47%174.61B6.15%111.71B10.27%56.9B12.46%215.82B
Operating expenses -7.87%-62.12B-13.63%-228.97B-14.22%-173.55B-19.50%-115.53B-16.19%-57.59B-7.59%-201.49B-9.10%-151.93B-5.98%-96.68B-11.02%-49.57B-13.38%-187.28B
Gross profit -7.03%8.03B2.76%31.33B5.67%23.96B13.51%17.06B17.80%8.63B6.81%30.49B4.45%22.68B7.26%15.03B5.41%7.33B6.79%28.54B
Selling expenses 15.86%-3.29B2.64%-13.9B-1.29%-10.47B-13.81%-7.73B-18.05%-3.91B-7.22%-14.28B-1.18%-10.34B-7.42%-6.79B-4.23%-3.31B-9.53%-13.32B
Administrative expenses -0.90%-1.39B-14.43%-5.71B-11.62%-4.19B-19.00%-2.76B-15.70%-1.38B2.95%-4.99B-5.09%-3.76B0.03%-2.32B2.57%-1.19B-8.70%-5.14B
Research and development expenses 7.26%-501.45M-4.35%-2.2B-5.70%-1.47B-26.76%-1.03B-20.82%-540.69M-6.29%-2.11B-1.63%-1.39B7.99%-809.67M-7.95%-447.5M-19.96%-1.99B
Profit from asset sales 405.21%110.04M-93.57%92.48M-92.67%104.58M-94.83%73.75M188.72%21.78M2,368.58%1.44B22,234.19%1.43B23,988.34%1.43B7,912.76%7.54M11.77%58.29M
Revaluation surplus -41.55%52.25M85.03%404.73M225.04%239.02M675.23%196.84M240.65%89.4M206.18%218.74M141.65%73.54M171.34%25.39M47.56%-63.56M-276.38%-206M
-Changes in the fair value of other assets -41.55%52.25M85.03%404.73M225.04%239.02M675.23%196.84M240.65%89.4M206.18%218.74M141.65%73.54M171.34%25.39M47.56%-63.56M-276.38%-206M
Impairment and provision -42.34%-241.8M-30.64%-841.24M-15.91%-262.6M-51.60%-270.22M-362.28%-169.87M-360.73%-643.93M13.13%-226.55M3.90%-178.24M60.88%-36.75M83.73%-139.76M
-Other impairment is provision -42.34%-241.8M-30.64%-841.24M-15.91%-262.6M-51.60%-270.22M-362.28%-169.87M-360.73%-643.93M13.13%-226.55M3.90%-178.24M60.88%-36.75M83.73%-139.76M
Special items of operating profit -34.56%233.27M-21.78%725.04M-49.72%346.45M-61.50%171.36M41.47%356.49M-59.88%926.88M-67.03%689.04M-76.12%445.11M-83.73%251.99M51.48%2.31B
Operating profit -4.11%2.79B-11.38%9.15B-10.54%7.71B-17.32%5.33B23.59%2.91B9.28%10.33B11.48%8.62B11.00%6.45B-28.85%2.35B12.19%9.45B
Financing cost 10.46%-374.43M-13.14%-1.49B-15.71%-1.15B-19.16%-773.22M-16.64%-418.18M-5.45%-1.31B-7.26%-997.59M-12.10%-648.91M-13.43%-358.53M-0.47%-1.25B
Special items of earning before tax 54.93%2.02M-197.11%-612.94M30.84%-36.96M41.10%-24.29M115.24%1.3M-234.51%-206.3M-1,031.28%-53.44M-228.25%-41.24M-261.75%-8.55M-592.50%-61.67M
Earning before tax -3.02%2.42B-19.91%7.05B-13.86%6.52B-21.26%4.53B25.44%2.49B8.16%8.81B11.35%7.57B10.36%5.76B-33.72%1.99B13.50%8.14B
Tax -2.28%-551.13M-3.93%-1.89B1.16%-1.57B6.45%-1.12B-18.63%-538.85M2.83%-1.82B-10.54%-1.58B-13.39%-1.19B26.63%-454.25M-19.04%-1.87B
After-tax profit from continuing operations -4.48%1.87B-26.11%5.17B-17.22%4.95B-25.14%3.42B27.46%1.95B11.43%6.99B11.56%5.98B9.59%4.56B-35.56%1.53B11.94%6.27B
Earning after tax -4.48%1.87B-26.11%5.17B-17.22%4.95B-25.14%3.42B27.46%1.95B11.43%6.99B11.56%5.98B9.59%4.56B-35.56%1.53B11.94%6.27B
Minority profit -25.75%323.29M1.72%1.4B-1.14%1.16B-7.07%807.18M54.77%435.4M16.41%1.37B33.04%1.17B45.49%868.61M9.10%281.31M6.50%1.18B
Profit attributable to shareholders 1.62%1.54B-32.92%3.77B-21.13%3.8B-29.38%2.61B21.31%1.52B10.28%5.62B7.35%4.81B3.58%3.7B-40.99%1.25B13.28%5.09B
Basic earnings per share 2.44%0.42-36.65%1.02-28.97%1.03-37.17%0.71-6.82%0.41-10.06%1.61-8.23%1.45-10.32%1.13-41.33%0.4413.29%1.79
Diluted earnings per share 2.44%0.42-36.65%1.02-28.97%1.03-37.17%0.71-6.82%0.41-10.06%1.61-8.23%1.45-10.32%1.13-41.33%0.4413.29%1.79
Currency Unit CNYCNYCNYCNYCNYCNYCNYCNYCNYCNY
Accounting Standards CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)
Audit Opinions --Unqualified Opinion------Unqualified Opinion------Unqualified Opinion
Auditor --PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership)------PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership)------PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership)

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
%Chg